Latest & greatest articles for sumatriptan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sumatriptan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sumatriptan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sumatriptan

1. Headache - cluster: Sumatriptan and zolmitriptan

Headache - cluster: Sumatriptan and zolmitriptan Sumatriptan and zolmitriptan | Prescribing information | Headache - cluster | CKS | NICE Search CKS… Menu Sumatriptan and zolmitriptan Headache - cluster: Sumatriptan and zolmitriptan Last revised in November 2017 Sumatriptan and zolmitriptan For detailed prescribing information on sumatriptan and zolmitriptan, see the section in the CKS topic on . The British National Formulary [ ] states that acute cluster headache is an indication (...) for: Sumatriptan by subcutaneous injection in adults. Sumatriptan by intranasal administration in adults aged 18–65 years. The British National Formulary [ ] states that acute cluster headache is an unlicensed indication for: Zolmitriptan by intranasal administration in adults. © .

2019 NICE Clinical Knowledge Summaries

2. Sumatriptan

Sumatriptan Top results for sumatriptan - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for sumatriptan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Bilateral Renal Infarctions During the Use of Sumatriptan (Full text)

Bilateral Renal Infarctions During the Use of Sumatriptan 30197992 2019 02 26 2468-0249 3 5 2018 Sep Kidney international reports Kidney Int Rep Bilateral Renal Infarctions During the Use of Sumatriptan. 1233-1236 10.1016/j.ekir.2018.05.003 Abramovitz Blaise B Renal Electrolyte and Hypertension Division, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Leonberg-Yoo Amanda A Renal Electrolyte and Hypertension Division, Perelman School of Medicine

2018 Kidney international reports PubMed abstract

4. Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis. (Abstract)

Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis. We performed this systematic review and meta-analysis to evaluate the tolerability and efficacy of intranasal sumatriptan, a selective serotonin agonist, compared to placebo or other migraine therapeutics for the treatment of acute migraine attacks. We searched PubMed, SCOPUS, Embase, and Cochrane CENTRAL for relevant randomized controlled trials (RCTs). Data were extracted from eligible studies and pooled (...) as risk ratios (RR), using RevMan software. We performed subgroup and meta-regression analyses for different doses and treatment endpoints. Sixteen RCTs (n = 5925 patients) matched our inclusion criteria. The overall effect-estimate showed that intranasal sumatriptan was superior to placebo in terms of pain relief (RR = 1.70, 95% CI [1.31, 2.21], p < 0.0001) and headache relief (RR = 1.58, 95% CI [1.35, 1.84], p < 0.00001) at 2 h. Although sumatriptan was superior to placebo in terms of headache

2017 Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

5. Sumatriptan for the treatment of acute migraine attacks

Sumatriptan for the treatment of acute migraine attacks '); } else { document.write(' '); } ACE| Sumatriptan for the treatment of acute migraine attacks Search > > Sumatriptan for the treatment of acute migraine attacks - Sumatriptan for the treatment of acute migraine attacks Published on 3 May 2017 Guidance Recommendations Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg tablet is recommended for listing on the MOH Standard Drug List 2 (SDL2 (...) ) by the MOH Drug Advisory Committee in view of its clinically superior outcomes when used in combination with naproxen compared with either sumatriptan or naproxen monotherapy, and the low cost of subsidy. This recommendation means that subsidies will apply to sumatriptan for the indications registered in Singapore: Acute relief of migraine attacks with or without aura, including the acute treatment of migraine attacks associated with the menstrual period in women. Quicklinks | | | | | Copyrights © 2019

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

6. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. (Full text)

Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. This is an updated version of the original Cochrane review published in October 2013 on 'Sumatriptan plus naproxen for acute migraine attacks in adults'.Migraine is a common disabling condition and a burden for the individual, health services, and society. It affects two to three times more women than men, and is most common in the age range 30 to 50 years. Effective abortive treatments include the triptan and non (...) -steroidal anti-inflammatory classes of drugs. These drugs have different mechanisms of action and combining them may provide better relief. Sumatriptan plus naproxen is now available in combination form for the acute treatment of migraine.To determine the efficacy and tolerability of sumatriptan plus naproxen, administered together as separate tablets or taken as a fixed-dose combination tablet, compared with placebo and other active interventions in the treatment of acute migraine attacks in adults.For

2016 Cochrane PubMed abstract

7. Systematic review: Is Metoclopramide more effective than Sumatriptan in relieving pain from migraine in adults in the Emergency Department (ED) setting? (Abstract)

Systematic review: Is Metoclopramide more effective than Sumatriptan in relieving pain from migraine in adults in the Emergency Department (ED) setting? Migraine headache is a common disorder; patients attending Emergency Departments (ED) for migraine symptoms internationally account for 1-3% of total ED annual attendances. A systematic review was undertaken of reports comparing the effectiveness of metoclopramide intravenously (IV) with that of sumatriptan subcutaneously (SC), in an ED setting

2016 International emergency nursing

8. Reduced efficacy of sumatriptan in migraine with aura vs without aura (Abstract)

Reduced efficacy of sumatriptan in migraine with aura vs without aura To determine whether acute migraine treatment outcome is different in migraine with aura compared with migraine without aura.We examined pooled outcome data for sumatriptan treatment of migraine with and without aura from the sumatriptan/naratriptan aggregate patient database. We also examined similar outcome data for inhaled dihydroergotamine (DHE) from a single, large randomized controlled study.The pooled pain-free rates 2 (...) hours postdose for sumatriptan 100 mg were significantly higher in patients treating attacks without aura (32%) compared with the group who treated attacks with aura (24%) (p < 0.001). The relative risk for pain freedom 2 hours postdose for attacks without aura was 1.33 (95% confidence interval: 1.16-1.54). The number needed to treat for 2 hours of pain freedom was 4.4 for attacks without aura and 6.2 for attacks with aura. For the clinical trial of DHE, the 2-hour pain-free rates did not differ

2015 EvidenceUpdates Controlled trial quality: uncertain

9. Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache?

Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache? SystematicReviewSnapshot TAKE-HOME MESSAGE Subcutaneous sumatriptan provides effective treatment of migraine headaches, quickly eliminating pain and associated symptoms; however, it has yet to be proven as an optimal emergency department (ED) treatment modality because of inadequate evidence of effectiveness in this setting, increased self-limiting adverse events (...) with subcutaneous su- matriptan to treat a migraine headache episode. DATA EXTRACTION AND SYNTHESIS Two review authors indepen- dently extracted data. Disagree- ments were resolved with the help of a third author. Relative risk was calculated with a ?xed- effect model. Numbers needed to treat were estimated with the Cook and Sackett 1 method. The quality of evidence was assessed using the Oxford Quality Scale. Is Subcutaneous Sumatriptan an Effective Treatment for Adults Presenting to the Emergency Department

2013 Annals of Emergency Medicine Systematic Review Snapshots

10. Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine (Full text)

Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine Treatment of adolescent migraine remains a significant unmet medical need. We compared the efficacy and safety of 3 doses of sumatriptan and naproxen sodium (suma/nap) combination tablets to placebo in the acute treatment of adolescent migraine.This randomized, parallel group study in 12 to 17 year olds required 2 to 8 migraines per month (typically lasting >3 hours untreated) for ≥ 6 months. Subjects entered

2012 EvidenceUpdates Controlled trial quality: predicted high PubMed abstract

11. WITHDRAWN: Oral sumatriptan for acute migraine. (Abstract)

WITHDRAWN: Oral sumatriptan for acute migraine. Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms. Sumatriptan is one of a class of selective serotonin 5-hydroxytryptamine (5-HT1B/1D) agonists (triptans) thought to relieve migraine attacks by several mechanisms, including cranial vasoconstriction and peripheral and central neural inhibition.To describe (...) and assess the evidence from randomized controlled trials (RCTs) concerning the efficacy and tolerability of oral sumatriptan for the treatment of a single acute attack of migraine in adults.We searched the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2001), MEDLINE (1966 through November 2001), and reference lists of articles and books.We included double-blind RCTs comparing oral sumatriptan (100 mg, 50 mg, 25 mg) with placebo, no intervention, other drug treatments

2012 Cochrane

12. Sumatriptan Galpharm

Sumatriptan Galpharm 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged London, 23 November 2011 EMA/40740/2012 Assessment Report Sumatriptan Galpharm 50 mg Tablets International non proprietary name: sumatriptan Procedure No. EMEA/H/C (...) /002140 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Sumatriptan 50 mg Tablets Perrigo Assessment Report EMA/40740/2012 Page 2/43 Table of contents 1 3 Background information on the procedure 1.1 3 Submission of the dossier 1.2 5 Steps taken for the re-examination of the product 2 5 Scientific discussion 2.1 5 Introduction 2.2 6 Quality aspects 2.3 10 Non- Clinical aspects 2.4 11 Clinical Aspects 2.5 21 Pharmacovigilance 3 25 Benefit-Risk

2012 European Medicines Agency - EPARs

13. Sumatriptan (oral route of administration) for acute migraine attacks in adults. (Full text)

Sumatriptan (oral route of administration) for acute migraine attacks in adults. Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy. Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family.To determine the efficacy and tolerability of oral sumatriptan compared to placebo and other active interventions in the treatment of acute migraine attacks in adults.We (...) searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, online databases, and reference lists for studies through 13 October 2011.We included randomised, double-blind, placebo- and/or active-controlled studies using oral sumatriptan to treat a migraine headache episode, with at least 10 participants per treatment arm.Two review authors independently assessed trial quality and extracted data. We used numbers of participants achieving each outcome to calculate relative

2012 Cochrane database of systematic reviews (Online) PubMed abstract

14. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. (Full text)

Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy. Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family. Rectal administration may be preferable to oral for individuals experiencing nausea and/or vomiting.To determine the efficacy and tolerability of rectal sumatriptan (...) compared to placebo and other active interventions in the treatment of acute migraine attacks in adults.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, online databases, and reference lists for studies through 13 October 2011.We included randomised, double-blind, placebo- and/or active-controlled studies using rectally administered sumatriptan to treat a migraine headache episode, with at least 10 participants per treatment arm.Two review authors independently

2012 Cochrane database of systematic reviews (Online) PubMed abstract

15. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. (Full text)

Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy. Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family. Intranasal administration may be preferable to oral for individuals experiencing nausea and/or vomiting, although it is primarily absorbed in the gut, not the nasal (...) mucosa.To determine the efficacy and tolerability of intranasal sumatriptan compared to placebo and other active interventions in the treatment of acute migraine attacks in adults.We searched Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, online databases, and reference lists for studies through 13 October 2011.We included randomised, double-blind, placebo- and/or active-controlled studies using intranasal sumatriptan to treat a migraine headache episode, with at least 10

2012 Cochrane database of systematic reviews (Online) PubMed abstract

16. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan (Full text)

Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan Multiple parenteral medications are used to treat migraine and other acute primary headaches in the emergency department (ED). Regardless of specific headache diagnosis, no medication eliminates the frequent recurrence of primary headache after ED discharge. It is uncertain which medication primary headache patients should be given on discharge from an ED. The aim (...) of this study is to compare the efficacy of oral sumatriptan with naproxen for treatment of post-ED recurrent primary headache.This was a randomized, double-blind efficacy trial. We randomized patients to either naproxen 500 mg or sumatriptan 100 mg for headache recurrence after ED discharge. Patients were eligible if they received parenteral therapy for an acute exacerbation of a primary headache in the ED. Patients who met established criteria for migraine without aura were designated a priori

2010 EvidenceUpdates Controlled trial quality: predicted high PubMed abstract

17. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department (Abstract)

A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department Intravenous (IV) prochlorperazine with diphenhydramine is superior to subcutaneous sumatriptan in the treatment of migraine patients presenting to the emergency department (ED).In this randomized, double-blind, placebo-controlled trial, after providing written informed consent, patients presenting to the ED with a chief complaint of migraine (...) received a 500-mL bolus of IV saline solution and either 10 mg prochlorperazine with 12.5 mg diphenhydramine IV plus saline solution placebo subcutaneously or saline solution placebo IV plus 6 mg sumatriptan subcutaneously. Pain intensity was assessed with 100-mm visual analog scales (visual analog scale at baseline and every 20 minutes for 80 minutes). The primary outcome was change in pain intensity from baseline to 80 minutes or time of ED discharge if subjects remained in the ED for fewer than 80

2010 EvidenceUpdates Controlled trial quality: predicted high

18. Alsuma (sumatriptan) injection

Alsuma (sumatriptan) injection Drug Approval Package: Alsuma (sumatriptan) NDA #022377 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Alsuma (sumatriptan) 6mg/0.5ml injection Company: King Pharmaceuticals, Inc. Application No.: 022377 Approval Date: 06/29/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2010 FDA - Drug Approval Package

19. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life (Abstract)

Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life To evaluate efficacy and tolerability of a single, fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan/naproxen sodium) vs placebo in migraineurs who had discontinued treatment with a short-acting triptan because of poor response or intolerance.Triptan monotherapy is ineffective or poorly tolerated in 1 of 3 migraineurs and in 2 of 5 migraine attacks. In April, 2008, the Food (...) and Drug Administration approved the combination therapy sumatriptan/naproxen sodium, developed specifically to target multiple migraine mechanisms. This combination product offers an alternative migraine therapy for patients who have reported poor response or intolerance to short-acting triptans.Two replicate, randomized, multicenter, double-blind, placebo-controlled, 2-attack crossover trials evaluated migraineurs who had discontinued a short-acting triptan in the past year because of poor response

2009 EvidenceUpdates Controlled trial quality: uncertain

20. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine (Abstract)

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome.To investigate the efficacy and tolerability of a fixed-dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine.Patients (aged 18 to 65 years (...) ) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while the pain was mild with either sumatriptan/naproxen or placebo. The primary efficacy measure was the percentage of patients who became pain-free 2 hours postdose.Intent-to-treat analyses consisted of 576 and 535 migraineurs. At 2

2008 EvidenceUpdates Controlled trial quality: predicted high